{"id":"W3087842901","doi":"10.1016/j.annonc.2020.08.438","title":"336P PI3K pathway biomarkers and clinical response in a phase I/Ib study of GDC-0077 in hormone receptor-positive/HER2-negative breast cancer (HR+/HER2– BC)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"EMD Serono; Genentech; PharmaMar; Springworks Therapeutics; MacroGenics; Silverback Therapeutics; Cilag; Puma Biotechnology; Relay Therapeutics; Eisai; Celltrion; Syndax Pharmaceuticals; Daiichi Sankyo Europe; National Cancer Institute; Servier; Calithera Biosciences; Unum Therapeutics; Amgen; Radius Health; Clovis Oncology; Les Laboratories Pierre Fabre; Genomic Health; Ipsen; Array BioPharma; Mersana Therapeutics; Karyopharm Therapeutics; NuCana; Pfizer; Incyte; Taiho Pharmaceutical; F. Hoffmann-La Roche; GlaxoSmithKline; Jounce Therapeutics; PTC Therapeutics; Celgene; Cancer Research Institute; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb; Sanofi","keywords":"Medicine; Palbociclib; Breast cancer; Internal medicine; Fulvestrant; Oncology; Cancer; Estrogen receptor; Metastatic breast cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001322533,0.0002630646,0.001300061,0.0002650194,0.00002784431,0.000003596655,0.0001565642,0.0002383055,0.000143705],"category_scores_gemma":[0.0006705572,0.0002431523,0.0001072603,0.0007074678,0.000631171,0.000139923,0.000117556,0.0004559295,0.000004306693],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001489231,"about_ca_system_score_gemma":0.0006205011,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002611407,"about_ca_topic_score_gemma":0.001279446,"domain_scores_codex":[0.9964531,0.001206566,0.001123415,0.0005666968,0.0002632582,0.0003869679],"domain_scores_gemma":[0.9974093,0.001242065,0.0005147361,0.0002559614,0.0003198248,0.000258052],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.3689398,0.01208208,0.1545401,0.0001113971,0.001138277,0.0006280114,0.02301065,0.0000256176,0.04769891,0.00001820792,0.0007788216,0.3910281],"study_design_scores_gemma":[0.03778508,0.04352536,0.900819,0.0002776927,0.00008290809,0.00004345651,0.01012616,0.00008172549,0.004797082,0.00007646932,0.002122044,0.0002630072],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9772983,0.0009935991,0.00001763991,0.0201289,0.00008922098,0.00108018,0.0002080329,0.00002032915,0.0001637889],"genre_scores_gemma":[0.9966328,0.0009194398,0.0004030719,0.001771938,0.0001137026,0.00009261355,0.000008026786,0.00003572552,0.00002273294],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7462789,"threshold_uncertainty_score":0.9915465,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09332269885895235,"score_gpt":0.4520226320281667,"score_spread":0.3586999331692143,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}